Microbiome may hold key to methotrexate response in RA

Save

Methotrexate (MTX) remains the cornerstone of rheumatoid arthritis (RA) treatment, yet it remains unclear as to how to predict who will respond to it. Two studies presented at ACR (Abstracts 2639 and 2643) suggest the answer may be hiding in the gut.

ACR25 Best Abstracts - Day 3

Save

Tweeting about an ACR presentation or poster is a skill and sometimes art -- one that is mastered by the RheumNow faculty roving the halls and floors for the best new insights at ACR Convergence 2025.

Accelerated Aging in Rheumatic Disease: From Biology to Lifestyle Intervention

Save

At ACR 2025, the session “27M02: Nutrition for Rheumatic Disease: Where Aging Biology, Sarcopenia, and Diet Intersect” invited the audience to view rheumatic disease through the lens of biological aging and to consider how nutrition and exercise can serve as integrative lifestyle interventions.

The Decade Ahead: Predicting Long-Term Proteinuria Risk in SLE

Save

The ACR Convergence 2025 in Chicago opens with engaging topics curated for the global rheumatologist. As a clinician, I always look forward to sessions that provide updates and practical key points that I can bring home and apply to my practice.

If We Can’t Prevent RA, Can We at Least Prevent Difficult-to-Treat RA?

Save

Two new studies presented this year tackle a key question: can our initial treatment choices influence who ends up in the difficult-to-treat category?

The Long View of Diagnostic Delay in Axial Spondyloarthritis

Save

Axial spondyloarthritis (axSpA) remains a diagnostic challenge, particularly in its early stages before structural sacroiliitis is visible on imaging.

ACR 2025 – Day 2 Report

Save

Here are 3 abstracts that caught my eye on Day 2 at ACR25. Notably these have takeaway messages that should support your current practices.

ACR25 Best Abstracts - Day 2

Save

After a full day at the Chicago Convention center the RheumNow faculty have posted some of their favorite reports included these that they labeled as being the "best' of day 2.

Are we putting the CAR-T before the horse?

Save

CAR T-cells have been a revolutionary development in rheumatology. We have seen a population of patients with severe refractory autoimmune conditions almost overnight presented with the prospect of not just improvement, but of a cure.

Psoriatic Arthritis: Which biologic agent is the best first choice?

Save

A growing arsenal of therapeutic targets in psoriatic arthritis (PsA) has enhanced the landscape of treatment in patients with this disease.

New Advances in Ultrasound Diagnostics for Psoriatic Arthritis

Save

Two pivotal studies led by an international team of rheumatology experts will be presented at ACR Convergence 2025, showcasing major strides in the ultrasound-based diagnosis of enthesitis in psoriatic arthritis (PsA).

Should we be using JAKi more in female SpA patients?

Save

In recent years, data has emerged suggesting that female patients with spondyloarthritis, both psoriatic arthritis and axial spondyloarthritis, may have worse outcomes than male patients. A number of post-hoc analyses of randomised controlled trials of both TNF inhibitors and IL-17 inhibitors suggest that this phenomenon is also manifested in the responses to these agents; female patients do less well than male patients. The mechanisms behind this remain to be fully elucidated.